Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

NCT02971839 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Decision by Sponsor.

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-561
DRUG: Placebo
DRUG: IVA

Sponsor

Vertex Pharmaceuticals Incorporated